Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8
暂无分享,去创建一个
Yi Zhou | Xuben Hou | Jintong Du | Hao Fang | Minyong Li | Renshuai Liu | Wenfang Xu | Minyong Li | Xuben Hou | H. Fang | Wenfang Xu | Renshuai Liu | Jintong Du | Yi Zhou | Yi Zhou
[1] K. Foon,et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study , 2014, Leukemia & lymphoma.
[2] Michael M. Mysinger,et al. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.
[3] Youyong Li,et al. Discovery of novel inhibitors targeting the macrophage migration inhibitory factor via structure-based virtual screening and bioassays. , 2014, Journal of medicinal chemistry.
[4] O. Wiest,et al. Zinc binding in HDAC inhibitors: a DFT study. , 2007, The Journal of organic chemistry.
[5] P. McCarren,et al. The Chemical Tuning of a Weak Zinc Binding Motif for Histone Deacetylase Using Electronic Effects , 2012, Chemical biology & drug design.
[6] M. Mrksich,et al. 3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition. , 2013, Journal of medicinal chemistry.
[7] Evgenia V. Dueva,et al. Inhibitors of tick-borne flavivirus reproduction from structure-based virtual screening. , 2013, ACS medicinal chemistry letters.
[8] C. Bountra,et al. Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.
[9] L. Klaman,et al. Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms , 2005, Molecular Pharmacology.
[10] Yong-Jun Jiang,et al. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. , 2008, Journal of molecular graphics & modelling.
[11] Nicolas Moitessier,et al. Docking Ligands into Flexible and Solvated Macromolecules. 6. Development and Application to the Docking of HDACs and other Zinc Metalloenzymes Inhibitors , 2014, J. Chem. Inf. Model..
[12] S. Altamura,et al. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. , 2009, Journal of medicinal chemistry.
[13] R. De Francesco,et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[14] M. Rowley,et al. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[15] Jian Zhang,et al. How to Improve Docking Accuracy of AutoDock4.2: A Case Study Using Different Electrostatic Potentials , 2013, J. Chem. Inf. Model..
[16] W. Guida,et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.
[17] C. Fierke,et al. Structures of metal-substituted human histone deacetylase 8 provide mechanistic inferences on biological function . , 2010, Biochemistry.
[18] R. Dror,et al. Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.
[19] Tingjun Hou,et al. Assessing an Ensemble Docking-Based Virtual Screening Strategy for Kinase Targets by Considering Protein Flexibility , 2014, J. Chem. Inf. Model..
[20] Yu Cao,et al. Virtual screening in small molecule discovery for epigenetic targets. , 2015, Methods.
[21] Patrisha Joseph Therese,et al. Multiple e-Pharmacophore Modeling, 3D-QSAR, and High-Throughput Virtual Screening of Hepatitis C Virus NS5B Polymerase Inhibitors , 2014, J. Chem. Inf. Model..
[22] Xun Li,et al. Interpretation of the Binding Affinities of PTP1B Inhibitors with the MM-GB/SA Method and the X-Score Scoring Function , 2009, J. Chem. Inf. Model..
[23] L. Ngo,et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[24] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[25] Ruibo Wu,et al. Flexibility of Catalytic Zinc Coordination in Thermolysin and HDAC8: A Born-Oppenheimer ab initio QM/MM Molecular Dynamics Study. , 2010, Journal of chemical theory and computation.
[26] A. W. Schüttelkopf,et al. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. , 2004, Acta crystallographica. Section D, Biological crystallography.
[27] M. K. Pflum,et al. Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.
[28] Yong Eun Kim,et al. A Structure‐Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc‐Chelating Groups , 2010, ChemMedChem.
[29] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[30] Xuben Hou,et al. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. , 2014, Journal of medicinal chemistry.
[31] Yan-tao Han,et al. Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy , 2015, Medicinal research reviews.
[32] Arthur J. Olson,et al. AutoDock4Zn: An Improved AutoDock Force Field for Small-Molecule Docking to Zinc Metalloproteins , 2014, J. Chem. Inf. Model..
[33] Yong-Jun Jiang,et al. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. , 2009, European journal of medicinal chemistry.
[34] M. Grunstein. Histone acetylation in chromatin structure and transcription , 1997, Nature.
[35] Takayoshi Suzuki,et al. Thermodynamics of Binding of Structurally Similar Ligands to Histone Deacetylase 8 Sheds Light on Challenges in the Rational Design of Potent and Isozyme-Selective Inhibitors of the Enzyme , 2014, Biochemistry.
[36] K. Glaser. HDAC inhibitors: clinical update and mechanism-based potential. , 2007, Biochemical pharmacology.
[37] Hao Tang,et al. Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation , 2009, J. Chem. Inf. Model..
[38] Ajay N. Jain. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.
[39] Peter M. Kasson,et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..
[40] M. Binaschi,et al. Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.
[41] O. Wiest,et al. Inhibition and Mechanism of HDAC8 Revisited , 2014, Journal of the American Chemical Society.
[42] Zhon-Yin Zhang,et al. Small molecule tools for functional interrogation of protein tyrosine phosphatases , 2013, The FEBS journal.
[43] M. Lübbert,et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy , 2010, Clinical Epigenetics.
[44] Gisbert Schneider,et al. Significance estimation for sequence-based chemical similarity searching (PhAST) and application to AuroraA kinase inhibitors. , 2012, Future medicinal chemistry.
[45] V. Castronovo,et al. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. , 2004, The American journal of pathology.
[46] Ø. Bruserud,et al. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. , 2007, Current pharmaceutical biotechnology.
[47] Ajay N. Jain,et al. Surflex-Dock: Docking benchmarks and real-world application , 2012, Journal of Computer-Aided Molecular Design.
[48] O. Wiest,et al. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.
[49] E. Seto,et al. Acetylation and deacetylation of non-histone proteins. , 2005, Gene.
[50] Ø. Bruserud,et al. Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells , 2007 .
[51] Vincent Zoete,et al. Toward On-The-Fly Quantum Mechanical/Molecular Mechanical (QM/MM) Docking: Development and Benchmark of a Scoring Function , 2014, J. Chem. Inf. Model..
[52] P. Soden,et al. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit. , 2013, Journal of medicinal chemistry.
[53] Y. Bang,et al. Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.
[54] J. Bradner,et al. On the inhibition of histone deacetylase 8. , 2010, Bioorganic & medicinal chemistry.
[55] M. Mrksich,et al. Synthesis and Structure−Activity Relationship of 3‐Hydroxypyridine- 2-thione-Based Histone Deacetylase Inhibitors , 2013 .
[56] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[57] Andrew R. Leach,et al. A Comparison of Field‐Based Similarity Searching Methods: CatShape, FBSS, and ROCS. , 2008 .
[58] Yixue Li,et al. Regulation of Cellular Metabolism by Protein Lysine Acetylation , 2010, Science.
[59] A. Anderson,et al. Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors. , 2013, ACS medicinal chemistry letters.
[60] Lenwood S. Heath,et al. H++: a server for estimating pKas and adding missing hydrogens to macromolecules , 2005, Nucleic Acids Res..
[61] S. Sakkiah,et al. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. , 2010, European journal of medicinal chemistry.
[62] Ruibo Wu,et al. Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. , 2011, Journal of the American Chemical Society.
[63] M. Esteller,et al. Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.
[64] Ruben Abagyan,et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. , 2010, Chemistry & biology.
[65] K. Bechtol,et al. Chunaram Choudhary Major Cellular Functions Lysine Acetylation Targets Protein Complexes and Co-Regulates , 2012 .
[66] K. Garber. HDAC inhibitors overcome first hurdle , 2007, Nature Biotechnology.
[67] Naresh Kandakatla,et al. Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors , 2014, Adv. Bioinformatics.
[68] R. De Francesco,et al. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complex , 2007, EMBO reports.
[69] Ruibo Wu,et al. A proton-shuttle reaction mechanism for histone deacetylase 8 and the catalytic role of metal ions. , 2010, Journal of the American Chemical Society.
[70] Seth M. Cohen,et al. Investigating the selectivity of metalloenzyme inhibitors. , 2013, Journal of medicinal chemistry.
[71] Richard A. Lewis,et al. Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.
[72] Giulia Russo,et al. Discovery of a novel small molecule inhibitor targeting the frataxin/ubiquitin interaction via structure-based virtual screening and bioassays. , 2013, Journal of medicinal chemistry.
[73] Stefano Alcaro,et al. Identification and characterization of new DNA G-quadruplex binders selected by a combination of ligand and structure-based virtual screening approaches. , 2013, Journal of medicinal chemistry.
[74] Terry P Lybrand,et al. Staggered Mesh Ewald: An extension of the Smooth Particle-Mesh Ewald method adding great versatility. , 2009, Journal of chemical theory and computation.
[75] M. K. Pflum,et al. Mutagenesis Studies of the 14 Å Internal Cavity of Histone Deacetylase 1: Insights toward the Acetate-Escape Hypothesis and Selective Inhibitor Design , 2014, Journal of medicinal chemistry.
[76] O. Wiest,et al. Computational exploration of zinc binding groups for HDAC inhibition. , 2013, The Journal of organic chemistry.
[77] H. Fang,et al. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. , 2011, Journal of medicinal chemistry.
[78] Berk Hess,et al. P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation. , 2008, Journal of chemical theory and computation.
[79] P. Coveney,et al. Loop Interactions and Dynamics Tune the Enzymatic Activity of the Human Histone Deacetylase 8 , 2013, Journal of the American Chemical Society.
[80] P. Geerlings,et al. DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors. , 2005, Bioorganic & medicinal chemistry.
[81] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[82] C. Fierke,et al. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors. , 2008, Biochemistry.
[83] E. Seto,et al. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.
[84] Lin-Li Li,et al. ID-Score: A New Empirical Scoring Function Based on a Comprehensive Set of Descriptors Related to Protein-Ligand Interactions , 2013, J. Chem. Inf. Model..
[85] P. Atadja,et al. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. , 2011, Bioorganic & medicinal chemistry.
[86] Adriano Martinelli,et al. Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities , 2009, J. Chem. Inf. Model..